Expressions and roles of serum IL-33 and sST2 in children with systemic lupus erythematosus

doi:10.3969/j.issn.1673-8640.2019.06.008

Abstract

Abstract:

Objective To investigate the expressions and roles of serum interleukin 33（IL-33）and soluble suppression of tumorigenicity 2（sST2） in children with systemic lupus erythematosus（SLE）. Methods Serum levels of IL-33 and sST2 in 32 children with SLE（SLE group） and 50 healthy children（healthy control group） were determined by enzyme-linked immunosorbent assay（ELISA）. The correlations between IL-33,sST2 and systemic lupus erythematosus disease activity index 2000（SLEDAI-2000）,anti-double-stranded DNA（anti-dsDNA） antibody were evaluated. Results Serum levels of IL-33 and sST2 were higher in SLE group than those in healthy control group（P<0.01）. Spearman correlation analysis showed that serum levels of IL-33 and sST2 in children with SLE were positively correlated with SLEDAI-2000（r=0.399 and 0.502,P=0.024 and 0.003,respectively）. Serum levels of IL-33 and sST2 in children with SLE were positively correlated with anti-dsDNA antibody（r=0.395 and 0.529,P=0.025 and 0.002,respectively）. Conclusions Serum IL-33 and sST2 may play roles in the pathogenesis of SLE among children.

Key words: Interleukin 33, Soluble suppression of tumorigenicity 2, Systemic lupus erythematosus, Disease activity

CLC Number:

R446.1

WANG Xia, SUO Minghuan, HU Ting, HU Yaozong, WEN Dongmei. Expressions and roles of serum IL-33 and sST2 in children with systemic lupus erythematosus[J]. Laboratory Medicine, 2019, 34(6): 518-521.

Figures/Tables 4

References 12

[1]	俞虹. 系统性红斑狼疮患者血清FER、CA125的检测及临床意义[J]. 检验医学,2018,33(2):182-184.
[2]	李池慧,郑冰,俞翀曌. 895例系统性红斑狼疮患者自身抗体检测结果的分析[J]. 检验医学,2018,33(5):463-465.
[3]	AGGARWAL A,SRIVASTAVA P.Childhood onest systemic lupus erythematosus:how is it different from adult SLE?[J]. Int J Rheum Dis,2015,8(2):182-191.
[4]	胡坚. 儿童系统性红斑狼疮去激素化治疗的思考[J]. 中华实用儿科临床杂志,2016,31(21):1608-1611.
[5]	PETRI M,ORBAI A M,ALARCÓN G S,et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum,2012,64(8):2677-2686.
[6]	MOK M Y,HUANG F P,IP W K,et al.Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus[J]. Rheumatology(Oxford),2010,49(3):520-527.
[7]	BOUFFI C,ROCHMAN M,ZUST C B,et al.IL-33 markedly activates murine eosinophils by an NF-κB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop[J]. J Immunol,2013,191(8):4317-4325.
[8]	LIVINGSTON B,BONNER A,POPE J.Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus:a meta-analysis[J]. Lupus,2011,20(15):1345-1355.
[9]	赵银霞,朱红娟,梁丽俊. 儿童系统性红斑狼疮的临床特点[J]. 宁夏医学杂志,2012,34(12):1251-1252.
[10]	LI P,LIN W,ZHENG X.IL-33 neutralization suppresses lupus disease in lupus-prone mice[J]. Inflammation,2014,37(3):824-832.
[11]	AKCAY A,NGUYEN Q,HE Z,et al.IL-33 exacerbates acute kidney injury[J]. J Am Soc Nephrol,2011,22(11):2057-2067.
[12]	YANG Z,LIANG Y,XI W,et al.Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population[J]. Clin Exp Med,2011,11(2):75-80.

组别	例数	IL-33	sST2
SLE组	32	24.5±5.0	990.2±350.7
正常对照组	50	13.9±3.2	284.9±69.1
t值		9.70	11.08
P值		0.004	0.000 1

组别	例数	IL-33	sST2
SLE组	32	24.5±5.0	990.2±350.7
正常对照组	50	13.9±3.2	284.9±69.1
t值		9.70	11.08
P值		0.004	0.000 1

[1]	HE Yaya, CHEN Shanshan, LI Yongsheng, LIU Juan. Expressions of sLAIR-1 and LAIR-1 mRNA in AS patients and their relationship with disease activity [J]. Laboratory Medicine, 2022, 37(10): 915-920.
[2]	ZHANG Wei, GUO Huijuan, WU Ximei, LING Xiuting, JIANG Xiaoxin, LIU Yunhong. Application value of serum sST2 level in monitoring rheumatoid arthritis and therapeutic effect [J]. Laboratory Medicine, 2021, 36(12): 1238-1242.
[3]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[4]	ZHANG Hongxia, HAN Hong. Changes and roles of sST2,SF and hepcidin levels in patients with CHF and anemia [J]. Laboratory Medicine, 2020, 35(9): 912-916.
[5]	LÜ Yingxia, YANG Junmei, ZHENG Lijuan, HUANG Qinghua. Expression of TLR-4 and HMGB1 in peripheral blood of children with SLE and its clinical significance [J]. Laboratory Medicine, 2020, 35(11): 1143-1146.
[6]	CHEN Yanhong, SUN Li, FU Yu, LIU Yan, NIU Guoping. Clinical application of plasma GAS5 in the diagnosis and treatment of systemic lupus erythematosus [J]. Laboratory Medicine, 2019, 34(8): 696-700.
[7]	XU Liming, SHEN Jun. Role of serum adiponectin determination combined with leptin in the diagnosis of lupus nephritis [J]. Laboratory Medicine, 2019, 34(5): 401-404.
[8]	YU Jianxiu, QIAN Lei, XU Donghui, LIU Guangliang. Determination of Tc9 cells in peripheral blood of infants with recurrent wheezing [J]. Laboratory Medicine, 2018, 33(4): 279-284.
[9]	TAN Liming, JIAO Anjun, FENG Xiaojing, XU Liuyue, TAN Fuyan, HE Siqi, LUO Heng, CHEN Juanjuan, JIANG Yongqing, LI Hua. Anti-neutrophil cytoplasmic antibody determination for systemic vasculitis [J]. Laboratory Medicine, 2018, 33(2): 101-105.
[10]	SONG Rui, YE Ping, CHEN Xiaoxiang. Correlations between IgG,IgM and IgA anti-ds-DNA antibodies and systemic lupus erythematosus [J]. Laboratory Medicine, 2018, 33(11): 969-974.
[11]	CHEN Shuimian, YU Chongzhao, LI Enling, ZHU Haoming, LU Jingbo, ZHENG Bing. Autoantibody-related parameters in patients with autoimmune diseases and healthy subjects [J]. Laboratory Medicine, 2018, 33(1): 31-36.
[12]	TAN Liming, DING Yaodong, CHEN Juanjuan, LI Hua, JIANG Yongqing, WAN Yani, WANG Liyun, WANG Tian. Complement 1q determination for autoimmune diseases [J]. Laboratory Medicine, 2017, 32(8): 686-690.
[13]	SONG Rui, YE Ping, WEI Chaohui, CHEN Xiaoxiang, WANG Jiucun. Correlation of systemic lupus erythematosus clinical phenotypes with anti-double-stranded DNA antibodies and performance comparison of 4 commercial determination kits [J]. Laboratory Medicine, 2017, 32(4): 316-321.
[14]	ZENG Huiqiong, FU Zhongchao, HUANG Xinmin, YIN Zhihua, YE Zhizhong. D-dimer,fibrinogen and transferrin for rheumatoid arthritis [J]. Laboratory Medicine, 2017, 32(10): 883-885.
[15]	XU Weijia 1，LI Zhi 1，YANG Tingting 2 ，WANG Bo 1. The changes and clinical significance on the expressions of Th17， Th1 and cytokines in patients with systemic lupus erythematosus [J]. , 2013, 28(5): 396-399.